Illumina's CEO Promises Growth By 2027, Because Patience Is A Strategy
Jacob Thaysen, Illumina's fearless captain navigating the turbulent biotech seas, insists they're still on course for a modest 'high single-digit revenue growth' by the distant shores of 2027. Despite unexpected headwinds—likely a fancy euphemism for market chaos, supply chain mayhem, or maybe his coffee machine breaking—the CEO remains optimistic. Illumina, known for turning DNA into some kind of money magic, apparently believes five more years of slow growth is an acceptable life strategy. It's 2024, investors might just want to pop some popcorn and enjoy the slowest rollercoaster ride in corporate history.
Share the Story
Illumina’s CEO is basically telling investors, 'Hang tight, it’s a glacier-speed race to glory by 2027,' because nothing screams excitement like three years to reach what a startup might pull off in six months.
Who needs quarterly fireworks when you can watch Illumina’s revenue growth crawl at a snail’s pace through 2027? CEO must think investors love suspenseful slow burns.
Illumina’s strategy: convince Wall Street that waiting for 'high single-digit growth' five years from now is a thrilling binge-watch, not a patience test.
Source: Statnews | Published: 8/26/2025 | Author: Jonathan Wosen
More Articles in Business
Salesforce AI Flops, Google Car-Dwellers & Senior Homebuyers Take Over
KPMG’s 450K Sq.Ft NYC HQ: Employee Feedback or Round Table Cult?
Rivian CEO’s $4.6B Stock Option: Billionaire or Billion Procrastinator?
DoorDash Execs Fail at Delivery, Beta-Test Their Own Chaos
Parenting & Two Jobs: Health Writer Floors Architectural Chaos!
